Company news

Viaderma, Inc. (OTC:VDRM) news

Viaderma, Inc. news releases on 6ix. Latest, Jul 16, 2025: ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response…

Viaderma, Inc. (OTC:VDRM) news

Press releases & updates

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India

ViaDerma Announces Significant 2024 Achievements and International Expansion

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria

ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key Hires

ViaDerma Provides Highlights of Quarterly Financial Report

ViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & More

ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More

ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product

ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product

ViaDerma Provides an Update on Current & Future Business Activities

ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development

ViaDerma Successfully Completes Quality Control Testing of its New Vitastem Products

ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products

ViaDerma's 2021 Annual Report Shows Strong Revenue Growth Over the Previous Year

ViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra

ViaDerma, Inc. Files Amended Financial Statements

ViaDerma, Inc. Provides Updates on Current Business Activities

ViaDerma, Inc. Announces Expansion of its Current Licensing Agreement and Provides Additional Company Updates

ViaDerma, Inc. Announces the Payment of all Toxic Convertible Notes and Has Become Debt Free

ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States

ViaDerma Inc., Provides Review of 2020 and Looks Forward to 2021

ViaDerma, Inc. Provides an Update on its Current Marketing Efforts

ViaDerma, Inc. Provides a Corporate Update

ViaDerma Provides an Update to Shareholders via a Letter from the CEO

ViaDerma Announces Increase of Amazon Sales on the Heels of U.S. Department of Commerce Trade Mission to India

United States Commerce Department Invites ViaDerma to Participate in Official Trade Mission to India

ViaDerma, Inc. Enters into a $250,000 Initial Sales Agreement with Vage Nigeria Ltd.

ViaDerma, Inc. Provides an Update of Current and Future Product Sales

ViaDerma, Inc. Provides an Update of Current Marketing Activities

ViaDerma, Inc. Refutes the Recent Announcement by Kasten, Inc.

U.S. District Court Rules Favorably for Kasten, Inc. on Basis of Legal Allegations Against Defendants Viaderma, Otiko and Phillips

ViaDerma, Inc. Announced the Dismissal of a Lawsuit Against Them in US District Federal Court

The Lawsuit against ViaDerma, Inc. has been Dismissed in US District Federal Court as the Company Vigorously Defends its Patents, Product Line and its Shareholders

ViaDerma, Inc. Announces Plan to Target Licensed Dispensaries in California after State Legalizes Recreational Marijuana & Seeks Reimbursement from Insurance Companies for its FDA Registered Topical Antibiotic Products

ViaDerma, Inc. Looks to have Sales Representatives Selling its FDA Registered Medication VitaStem to a Network of 1000 Physician Offices Nationwide in 2018

ViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products

ViaDerma, Inc. Commences Distribution of VitaStem(TM), its FDA Registered Topical Antibiotic, and Looks to Expand its Partnership with Biogenx

ViaDerma, Inc. Eyes Deal to Place its Patent Pending MMJ Technology into 400 Canadian Retail Stores and an on-line store via the Web, through its Management, Marketing and Distribution Partner in Canada

ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan

ViaDerma, Inc. Starts Phase II of MMJ and Recreational Testing in Canada, also is Now Fast Tracking its Topical Antibiotic with the BFAD (Bureau of Food and Drugs) in Philippines for Approval of its FDA Registered Product

ViaDerma, Inc. will Seek BFAD (Bureau of Food and Drugs) Approval for its topical antibiotic in the Philippines as Preliminary Studies for the FDA Registered Product Show Promising Results

ViaDerma, Inc. Receives National Drug Code (NDC) from the FDA for Prolayed, Its New OTC Drug for Premature Ejaculation for Men

ViaDerma, Inc. Begins Consumer Testing on its Topical Antibiotic in the Philippines Due to Country Wide Interest from Distributors as it Eyes Huge Market for Several New Follow-on Products with Registration Numbers from the FDA Soon to Follow

ViaDerma, Inc. Commences First Manufacturing Run and will Meet the 2nd Quarter Product Distribution Milestone

ViaDerma, Inc. Receives Positive Results on Phase I Testing in Canada with its Proprietary THC Delivery and Moves to Phase II Trials and development of New Products with its MMJ Technologies

ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company